The GA4GH Phenopacket schema defines a computable representation of clinical data.
Ontology highlight
ABSTRACT:
SUBMITTER: Jacobsen JOB
PROVIDER: S-EPMC9363006 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
Publications
The GA4GH Phenopacket schema defines a computable representation of clinical data.
Jacobsen Julius O B JOB Baudis Michael M Baynam Gareth S GS Beckmann Jacques S JS Beltran Sergi S Buske Orion J OJ Callahan Tiffany J TJ Chute Christopher G CG Courtot Mélanie M Danis Daniel D Elemento Olivier O Essenwanger Andrea A Freimuth Robert R RR Gargano Michael A MA Groza Tudor T Hamosh Ada A Harris Nomi L NL Kaliyaperumal Rajaram R Lloyd Kevin C Kent KCK Khalifa Aly A Krawitz Peter M PM Köhler Sebastian S Laraway Brian J BJ Lehväslaiho Heikki H Matalonga Leslie L McMurry Julie A JA Metke-Jimenez Alejandro A Mungall Christopher J CJ Munoz-Torres Monica C MC Ogishima Soichi S Papakonstantinou Anastasios A Piscia Davide D Pontikos Nikolas N Queralt-Rosinach Núria N Roos Marco M Sass Julian J Schofield Paul N PN Seelow Dominik D Siapos Anastasios A Smedley Damian D Smith Lindsay D LD Steinhaus Robin R Sundaramurthi Jagadish Chandrabose JC Swietlik Emilia M EM Thun Sylvia S Vasilevsky Nicole A NA Wagner Alex H AH Warner Jeremy L JL Weiland Claus C Haendel Melissa A MA Robinson Peter N PN
Nature biotechnology 20220601 6
Similar Datasets
Project description:Maximizing the personal, public, research, and clinical value of genomic information will require the reliable exchange of genetic variation data. We report here the Variation Representation Specification (VRS, pronounced "verse"), an extensible framework for the computable representation of variation that complements contemporary human-readable and flat file standards for genomic variation representation. VRS provides semantically precise representations of variation and leverages this design to enable federated identification of biomolecular variation with globally consistent and unique computed identifiers. The VRS framework includes a terminology and information model, machine-readable schema, data sharing conventions, and a reference implementation, each of which is intended to be broadly useful and freely available for community use. VRS was developed by a partnership among national information resource providers, public initiatives, and diagnostic testing laboratories under the auspices of the Global Alliance for Genomics and Health (GA4GH).
| S-EPMC8929418 | biostudies-literature
Project description:ObjectivesThe Patient, Intervention, Control/Comparison, and Outcome (PICO) framework is an effective technique for framing a clinical question. We aim to develop the counterpart of PICO to structure clinical research data needs.MethodsWe use a data-driven approach to abstracting key concepts representing clinical research data needs by adapting and extending an expert-derived framework originally developed for defining cancer research data needs. We annotated clinical trial eligibility criteria, EHR data request logs, and data queries to electronic health records (EHR), to extract and harmonize concept classes representing clinical research data needs. We evaluated the class coverage, class preservation from the original framework, schema generalizability, schema understandability, and schema structural correctness through a semi-structured interview with eight multidisciplinary domain experts. We iteratively refined the schema based on the evaluations.ResultsOur data-driven schema preserved 68% of the 63 classes from the original framework and covered 88% (73/82) of the classes proposed by evaluators. Class coverage for participants of different backgrounds ranged from 60% to 100% with a median value of 95% agreement among the individual evaluators. The schema was found understandable and structurally sound.ConclusionsOur proposed schema may serve as the counterpart to PICO for improving the research data needs communication between researchers and informaticians.
| S-EPMC4873775 | biostudies-literature
Project description:True and false intentions (i.e., lies and truths about one's future actions) is a relatively new research topic, despite the high societal value of being able to predict future criminal behavior (e.g., in the case of an alleged terrorist attack). The current study examined how true and false intentions are mentally represented - the knowledge of which can aid the development of new deception detection methods. Participants (N = 151) were asked either to form a true intention about a future task (i.e., retrieve objects from an office) or to form a false intention about the same task (i.e., prepare a cover story about retrieving objects from an office) to conceal their actual intention (i.e., leave a secret note in the office). The schema consistency of the task was manipulated by presenting participants with a list of office supplies (schema-consistent) or random objects (schema-inconsistent) to be retrieved from the office. The abstractness of mental construal was operationalized as the number of categories used by participants to organize the task-relevant objects into thematic groups. We predicted, based on construal level theory (CLT) and action identification theory, that participants would mentally represent true intentions more concretely (i.e., use a larger number of categories) than false intentions, particularly for schema-inconsistent (versus schema-consistent) future tasks. The results of the study lend no support for these predictions. Instead, a Bayesian analysis revealed strong evidence in favor of the null hypothesis. The findings indicate that predictions from CLT do not readily translate into deception contexts. The results are discussed in light of recent failed attempts to apply CLT to research on true and false intentions, and highlight the need for alternative approaches to the topic.
| S-EPMC6682835 | biostudies-literature
Project description:It is widely accepted that large-scale genomic data (e.g., whole-genome sequencing, whole-exome sequencing, and genome-wide association study data) be shared through a controlled-access mechanism. This protects the privacy of research participants and ensures downstream uses of data align with participants' informed consent regarding future sharing of their data. In 2019, GA4GH approved the Data Use Ontology (DUO) standard to define data use terms with machine-readable representations to represent how a dataset can be used. We endeavored to determine the parity of existing data use restrictions ("Data Use Limitations" [DULs]) for datasets registered in the National Institutes of Health database for Genotypes and Phenotypes (dbGaP) with the DUO standard. We found substantial (93%) parity between the dbGaP DULs (n = 3,575) and DUO. This study demonstrates the comprehensiveness of the DUO standard and encourages data stewards to standardize data use restrictions in machine-readable formats to facilitate data sharing.
| S-EPMC10504671 | biostudies-literature
Project description: Not available
| S-EPMC9969330 | biostudies-literature
Project description:The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits.
| S-EPMC8774288 | biostudies-literature
Project description:ObjectivesThere exists a communication gap between the biomedical informatics community on one side and the computer science/artificial intelligence community on the other side regarding the meaning of the terms "semantic integration" and "knowledge representation". This gap leads to approaches that attempt to provide one-to-one mappings between data elements and biomedical ontologies. Our aim is to clarify the representational differences between traditional data management and semantic-web-based data management by providing use cases of clinical data and clinical research data re-representation. We discuss how and why one-to-one mappings limit the advantages of using Semantic Web Technologies (SWTs).MethodsWe employ commonly used SWTs, such as Resource Description Framework (RDF) and Ontology Web Language (OWL). We reuse pre-existing ontologies and ensure shared ontological commitment by selecting ontologies from a framework that fosters community-driven collaborative ontology development for biomedicine following the same set of principles.ResultsWe demonstrate the results of providing SWT-compliant re-representation of data elements from two independent projects managing clinical data and clinical research data. Our results show how one-to-one mappings would hinder the exploitation of the advantages provided by using SWT.ConclusionsWe conclude that SWT-compliant re-representation is an indispensable step, if using the full potential of SWT is the goal. Rather than providing one-to-one mappings, developers should provide documentation that links data elements to graph structures to specify the re-representation.
| S-EPMC6697506 | biostudies-literature
Project description:The Global Alliance for Genomics and Health (GA4GH) is developing a suite of coordinated standards for genomics for healthcare. The Phenopacket is a new GA4GH standard for sharing disease and phenotype information that characterizes an individual person, linking that individual to detailed phenotypic descriptions, genetic information, diagnoses, and treatments. A detailed example is presented that illustrates how to use the schema to represent the clinical course of a patient with retinoblastoma, including demographic information, the clinical diagnosis, phenotypic features and clinical measurements, an examination of the extirpated tumor, therapies, and the results of genomic analysis. The Phenopacket Schema, together with other GA4GH data and technical standards, will enable data exchange and provide a foundation for the computational analysis of disease and phenotype information to improve our ability to diagnose and conduct research on all types of disorders, including cancer and rare diseases.
| S-EPMC10000265 | biostudies-literature
Project description:BackgroundPhenotypic data comparison is essential for disease association studies, patient stratification, and genotype-phenotype correlation analysis. To support these efforts, the Global Alliance for Genomics and Health (GA4GH) established Phenopackets v2 and Beacon v2 standards for storing, sharing, and discovering genomic and phenotypic data. These standards provide a consistent framework for organizing biological data, simplifying their transformation into computer-friendly formats. However, matching participants using GA4GH-based formats remains challenging, as current methods are not fully compatible, limiting their effectiveness.ResultsHere, we introduce Pheno-Ranker, an open-source software toolkit for individual-level comparison of phenotypic data. As input, it accepts JSON/YAML data exchange formats from Beacon v2 and Phenopackets v2 data models, as well as any data structure encoded in JSON, YAML, or CSV formats. Internally, the hierarchical data structure is flattened to one dimension and then transformed through one-hot encoding. This allows for efficient pairwise (all-to-all) comparisons within cohorts or for matching of a patient's profile in cohorts. Users have the flexibility to refine their comparisons by including or excluding terms, applying weights to variables, and obtaining statistical significance through Z-scores and p-values. The output consists of text files, which can be further analyzed using unsupervised learning techniques, such as clustering or multidimensional scaling (MDS), and with graph analytics. Pheno-Ranker's performance has been validated with simulated and synthetic data, showing its accuracy, robustness, and efficiency across various health data scenarios. A real data use case from the PRECISESADS study highlights its practical utility in clinical research.ConclusionsPheno-Ranker is a user-friendly, lightweight software for semantic similarity analysis of phenotypic data in Beacon v2 and Phenopackets v2 formats, extendable to other data types. It enables the comparison of a wide range of variables beyond HPO or OMIM terms while preserving full context. The software is designed as a command-line tool with additional utilities for CSV import, data simulation, summary statistics plotting, and QR code generation. For interactive analysis, it also includes a web-based user interface built with R Shiny. Links to the online documentation, including a Google Colab tutorial, and the tool's source code are available on the project home page: https://github.com/CNAG-Biomedical-Informatics/pheno-ranker .
| S-EPMC11616229 | biostudies-literature
Project description:BackgroundPharmacovigilance consists in monitoring and preventing the occurrence of adverse drug reactions (ADR). This activity requires the collection and analysis of data from the patient record or any other sources to find clues of a causality link between the drug and the ADR. This can be time-consuming because often patient data are heterogeneous and scattered in several files. To facilitate this task, we developed a timeline prototype to gather and classify patient data according to their chronology. Here, we evaluated its usability and quantified its contribution to routine pharmacovigilance using real ADR cases.MethodsThe timeline prototype was assessed using the biomedical data warehouse eHOP (from entrepôt de données biomédicales de l'HOPital) of the Rennes University Hospital Centre. First, the prototype usability was tested by six experts of the Regional Pharmacovigilance Centre of Rennes. Their experience was assessed with the MORAE software and a System and Usability Scale (SUS) questionnaire. Then, to quantify the timeline contribution to pharmacovigilance routine practice, three of them were asked to investigate possible ADR cases with the "Usual method" (analysis of electronic health record data with the DxCare software) or the "Timeline method". The time to complete the task and the data quality in their reports (using the vigiGrade Completeness score) were recorded and compared between methods.ResultsAll participants completed their tasks. The usability could be considered almost excellent with an average SUS score of 82.5/100. The time to complete the assessment was comparable between methods (P = 0.38) as well as the average vigiGrade Completeness of the data collected with the two methods (P = 0.49).ConclusionsThe results showed a good general level of usability for the timeline prototype. Conversely, no difference in terms of the time spent on each ADR case and data quality was found compared with the usual method. However, this absence of difference between the timeline and the usual tools that have been in use for several years suggests a potential use in pharmacovigilance especially because the testers asked to continue using the timeline after the evaluation.
| S-EPMC6194681 | biostudies-literature